GT Biopharma, Inc. (GTBP)
0.299
-0.01
(-2.22%)
USD |
NASDAQ |
Aug 25, 16:00
0.299
0.00 (0.00%)
After-Hours: 19:59
GT Biopharma EPS Diluted (Quarterly) : -0.1183 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1183 |
| March 31, 2026 | -0.1112 |
| December 31, 2025 | -4.413 |
| September 30, 2025 | 1.040 |
| June 30, 2025 | -10.92 |
| March 31, 2025 | -0.3309 |
| December 31, 2024 | -1.690 |
| September 30, 2024 | -1.527 |
| June 30, 2024 | -2.167 |
| March 31, 2024 | -1.641 |
| December 31, 2023 | -2.145 |
| September 30, 2023 | -1.767 |
| June 30, 2023 | -1.488 |
| March 31, 2023 | -0.1743 |
| December 31, 2022 | -5.120 |
| September 30, 2022 | -6.578 |
| June 30, 2022 | -2.861 |
| March 31, 2022 | -5.024 |
| December 31, 2021 | -16.86 |
| September 30, 2021 | -5.213 |
| June 30, 2021 | -4.351 |
| March 31, 2021 | -54.82 |
| December 31, 2020 | -85.85 |
| September 30, 2020 | -19.11 |
| June 30, 2020 | -123.58 |
| Date | Value |
|---|---|
| March 31, 2020 | -12.43 |
| December 31, 2019 | -10.74 |
| September 30, 2019 | -259.12 |
| June 30, 2019 | -27.40 |
| March 31, 2019 | -45.02 |
| December 31, 2018 | -42.60 |
| September 30, 2018 | -2397.58 |
| June 30, 2018 | -91.80 |
| March 31, 2018 | -102.00 |
| December 31, 2017 | -61.32 |
| September 30, 2017 | -4156.48 |
| June 30, 2017 | -786420.0 |
| March 31, 2017 | -4.033M |
| December 31, 2016 | -13843.44 |
| September 30, 2016 | -19890.00 |
| June 30, 2016 | 9180.00 |
| March 31, 2016 | 128520.0 |
| December 31, 2015 | -1.371M |
| September 30, 2015 | -107865.0 |
| June 30, 2015 | 765000.0 |
| March 31, 2015 | -1.148M |
| December 31, 2014 | -1.204M |
| September 30, 2014 | -273487.5 |
| June 30, 2014 | -17595.00 |
| March 31, 2014 | -24862.50 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.518M |
| Total Expenses (Quarterly) | 4.518M |
| Enterprise Value | 8.607M |
| Earnings Yield | -1.20K% |
| Normalized Earnings Yield | -2304.85 |